Ziprasidone Mesylate
5 NDCs across 3 manufacturers|5 Generic,0 Brand
Ziprasidone Mesylate is used to treat schizophrenia and tourette syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jun 21, 2002, and the first generic was approved Dec 26, 2019. In 2024, Medicare Part D spent $514K on Ziprasidone Mesylate across 2,863 claims for 1,309 beneficiaries.
Ziprasidone Mesylate is available as 5 NDCs from 3 manufacturers (5 generic, 0 brand), with NADAC prices from $21.81 to $21.81 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
5
5G / 0B
Manufacturers
3
competing in market
Price Spread
$21.81 – $21.81
per EA
7d Activity
avg +0.0% WoW · of 5 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Dr. Reddy's Laboratories Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Atypical Antipsychotic class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
3 manufacturers producing ZIPRASIDONE MESYLATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ZIPRASIDONE 20 MG/ML VIAL | $21.8074 per EA | — |
ZIPRASIDONE 20 MG/ML VIAL | $21.8074 per EA | — |
ZIPRASIDONE 20 MG/ML VIAL | $21.8074 per EA | — |
ZIPRASIDONE 20 MG/ML VIAL | $21.8074 per EA | — |
ZIPRASIDONE 20 MG/ML VIAL | $21.8074 per EA | — |
Frequently Asked Questions
What is Ziprasidone Mesylate used to treat?
Ziprasidone Mesylate is used to treat schizophrenia and tourette syndrome, per the National Library of Medicine's MED-RT classification.
When did Ziprasidone Mesylate become available as a generic?
FDA approved the first generic Ziprasidone Mesylate (ANDA) on Dec 26, 2019.
How much does Medicare spend on Ziprasidone Mesylate?
In 2024, Medicare Part D spent $514K on Ziprasidone Mesylate across 2,863 claims for 1,309 beneficiaries.
How many Ziprasidone Mesylate products are on the market?
The Ziprasidone Mesylate drug market contains 5 NDCs from 3 manufacturers — 5 generic and 0 brand products.
What is the price range for Ziprasidone Mesylate?
NADAC reference prices for Ziprasidone Mesylate range from $21.8074 to $21.8074 per EA.
Which manufacturers make Ziprasidone Mesylate?
3 manufacturers list Ziprasidone Mesylate in NADAC. Ranked by number of NDCs, the largest are Dr. Reddy's Laboratories Inc. (2), Fosun Pharma USA Inc. (2), Novadoz Pharmaceuticals LLC (1).